Teleflex (TFX) came out with quarterly earnings of $3.42 per share, beating the Zacks Consensus Estimate of $3.33 per share. This compares to earnings of $3.41 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 2.70%. A quarter ago, it was expected that this medical equipment maker would post earnings of $3.07 per share when it actually produced earnings of $3.21, delivering a surprise of 4.56%.Over the last four quarters, the co ...

财务业绩 - 公司第二季度GAAP收入为7.497亿美元，同比增长0.9%[4] - 公司调整后收入为7.635亿美元，剔除与意大利退款相关的影响后同比增长2.7%，按固定汇率计算同比增长3.4%[5] - 公司调整后每股摊薄收益为3.42美元，与上年同期持平[5] - 公司2024年第二季度总收入为7.497亿美元，同比增长2.3%[55] - 公司2024年上半年总收入为14.875亿美元，同比增长2.3%[59] - 公司2024年第二季度调整后毛利率为60.8%，同比增加4.2个百分点[55] - 公司2024年上半年调整后毛利率为60.9%，同比增加4.9个百分点[59] - 公司2024年第二季度调整后营业利润率为26.7%，同比增加7.4个百分点[55] - 公司2024年上半年调整后营业利润率为26.7%，同比增加5.1个百分点[59] - 公司2024年第二季度调整后每股收益为3.42美元，同比增长0.01美元[55] - 公司2024年上半年调整后每股收益为6.63美元，同比增长0.13美元[59] - 公司2024年上半年净收入为14.875亿美元，同比增长2.3%[69] - 2024年上半年毛利润为8.326亿美元，毛利率为56.0%[69] - 2024年上半年研发费用为7839万美元，占净收入的5.3%[69] - 2024年上半年重组和减值费用为1051万美元[69] - 2024年上半年持续经营业务税前利润为7.17亿美元[69] 非GAAP财务指标 - 公司报告的财务业绩符合会计准则(GAAP)，同时提供了一些非GAAP财务指标以供参考[31] - 非GAAP财务指标包括经调整收入、经调整汇率不变收入增长和经调整每股摊薄收益[31] - 公司剔除了与意大利医疗设备退款相关的13.8百万美元前期费用，将其从收入中扣除[33] - 公司剔除了汇率变动的影响，以便更好地反映其业务表现[34] - 公司剔除了重组、收购整合、退休金终止等一次性费用，以更好地反映其核心业务表现[36][37][38][40] - 公司将与欧盟医疗器械法规相关的新注册费用从经调整指标中剔除[41] - 公司将新ERP系统实施相关的直接成本从经调整指标中剔除[43] - 公司2024年上半年因意大利退款措施而增加13.8亿美元的收入调整[54,59,65] - 公司2024年上半年因退休金终止成本而增加13.86亿美元的调整[59] 现金流和资产负债 - 公司现金及现金等价物为2.386亿美元，较2023年12月31日增加1.58亿美元[18] - 公司存货为6.369亿美元，较2023年12月31日增加1.07亿美元[19] - 2024年6月30日现金及现金等价物余额为2.386亿美元[72] - 2024年6月30日总资产为74.416亿美元[72] - 2024年6月30日总负债为28.829亿美元[72] - 2024年6月30日股东权益为45.587亿美元[72] - 2024年上半年经营活动产生的现金流入为2.045亿美元[74] 业务展望 - 公司上调2024年GAAP收入增长指引至3.40%至4.40%[6] - 公司上调2024年调整后固定汇率收入增长指引至4.25%至5.25%，剔除意大利退款相关影响[7] - 公司下调2024年GAAP每股收益指引至6.43美元至6.83美元[21] - 公司上调2024年调整后每股收益指引至13.80美元至14.20美元[21] 其他 - 公司宣布启动总额不超过5亿美元的股票回购计划，其中包括2亿美元的加速回购计划[8,24] - 公司在各地区和产品线的收入情况[45][46][50][51]

WAYNE, Pa., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable September 16, 2024, to shareholders of record at the close of business on August 15, 2024. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to ...

WAYNE, Pa., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable September 16, 2024, to shareholders of record at the close of business on August 15, 2024. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to ...

WAYNE, Pa., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the second quarter ended June 30, 2024. Second quarter financial summary GAAP revenue of $749.7 million, up 0.9% compared to the prior year period Adjusted revenue of $763.5 million, excluding the impact from increases in our reserves related to the Italian payback measure pertaining to prior years, up 2.7% compared to the prior year period, up 3.4% on a constant currency bas ...

Analysts on Wall Street project that Teleflex (TFX) will announce quarterly earnings of $3.33 per share in its forthcoming report, representing a decline of 2.4% year over year. Revenues are projected to reach $763.39 million, increasing 2.7% from the same quarter last year.Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.Ahead of a com ...

WAYNE, Pa., July 31, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the Ringer™ Perfusion Balloon Catheter (PBC), the only commercially available Percutaneous Transluminal Coronary Angioplasty (PTCA) perfusion balloon.1 The Ringer™ PBC is a rapid-exchange 0.014” compatible catheter with a unique helical balloon at its working end. When inflated, this balloon approximate ...

WAYNE, Pa., July 31, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the Ringer™ Perfusion Balloon Catheter (PBC), the only commercially available Percutaneous Transluminal Coronary Angioplasty (PTCA) perfusion balloon.1 The Ringer™ PBC is a rapid-exchange 0.014" compatible catheter with a unique helical balloon at its working end. When inflated, this balloon approximates ...

WAYNE, Pa., July 29, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced it was awarded two group purchasing agreements with Premier, Inc. Effective July 1, 2024, the Premier National Hemostasis Products and SURPASS® Hemostasis Products agreements allow Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Teleflex products within the hemostatic portfolio. Premier's SURPASS® ...

WAYNE, Pa., July 29, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it was awarded two group purchasing agreements with Premier, Inc. Effective July 1, 2024, the Premier National Hemostasis Products and SURPASS® Hemostasis Products agreements allow Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Teleflex products within the hemostatic portfolio. Premier’s SURPASS ...